SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Endo International plc

Levi & Korsinsky announces it has commenced an investigation of Endo International plc ENDP concerning possible violations of federal securities laws. On June 8, 2017, the U.S. Food and Drug Administration (the "FDA") requested Endo pull its opioid painkiller OPANA ER off the U.S. market. According to the FDA, Opana's "high risk of abuse and potential to help spread HIV and hepatitis C" necessitated its removal from the market. To obtain additional information, go to:

http://www.zlkdocs.com/ENDP-Info-Request-Form-4315

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170609005673/en/